KalVista Pharmaceuticals (KALV) Retained Earnings (2016 - 2024)
Historic Retained Earnings for KalVista Pharmaceuticals (KALV) over the last 10 years, with Q4 2024 value amounting to -$580.2 million.
- KalVista Pharmaceuticals' Retained Earnings changed N/A to -$580.2 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$580.2 million, marking a year-over-year change of. This contributed to the annual value of -$469.7 million for FY2024, which is N/A changed from last year.
- Per KalVista Pharmaceuticals' latest filing, its Retained Earnings stood at -$580.2 million for Q4 2024.
- KalVista Pharmaceuticals' Retained Earnings' 5-year high stood at -$115.0 million during Q1 2020, with a 5-year trough of -$580.2 million in Q4 2024.
- Moreover, its 4-year median value for Retained Earnings was -$382.2 million (2023), whereas its average is -$330.6 million.
- Per our database at Business Quant, KalVista Pharmaceuticals' Retained Earnings crashed by 3148.49% in 2020 and then tumbled by 3948.7% in 2024.
- Quarter analysis of 4 years shows KalVista Pharmaceuticals' Retained Earnings stood at -$142.8 million in 2020, then fell by 7.03% to -$152.9 million in 2021, then tumbled by 159.06% to -$396.0 million in 2023, then tumbled by 46.49% to -$580.2 million in 2024.
- Its Retained Earnings was -$580.2 million in Q4 2024, compared to -$552.4 million in Q4 2024 and -$510.2 million in Q3 2024.